1. Home
  2. MEIP vs WKHS Comparison

MEIP vs WKHS Comparison

Compare MEIP & WKHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • WKHS
  • Stock Information
  • Founded
  • MEIP 2000
  • WKHS 2007
  • Country
  • MEIP United States
  • WKHS United States
  • Employees
  • MEIP N/A
  • WKHS N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • WKHS Auto Manufacturing
  • Sector
  • MEIP Health Care
  • WKHS Consumer Discretionary
  • Exchange
  • MEIP Nasdaq
  • WKHS Nasdaq
  • Market Cap
  • MEIP 19.5M
  • WKHS 19.5M
  • IPO Year
  • MEIP 2003
  • WKHS N/A
  • Fundamental
  • Price
  • MEIP $2.78
  • WKHS $1.10
  • Analyst Decision
  • MEIP Hold
  • WKHS Sell
  • Analyst Count
  • MEIP 2
  • WKHS 3
  • Target Price
  • MEIP $7.00
  • WKHS $5.75
  • AVG Volume (30 Days)
  • MEIP 53.1K
  • WKHS 5.2M
  • Earning Date
  • MEIP 11-12-2024
  • WKHS 11-19-2024
  • Dividend Yield
  • MEIP N/A
  • WKHS N/A
  • EPS Growth
  • MEIP N/A
  • WKHS N/A
  • EPS
  • MEIP N/A
  • WKHS N/A
  • Revenue
  • MEIP N/A
  • WKHS $9,097,780.00
  • Revenue This Year
  • MEIP N/A
  • WKHS N/A
  • Revenue Next Year
  • MEIP $300.00
  • WKHS $236.05
  • P/E Ratio
  • MEIP N/A
  • WKHS N/A
  • Revenue Growth
  • MEIP 33.76
  • WKHS N/A
  • 52 Week Low
  • MEIP $2.61
  • WKHS $0.57
  • 52 Week High
  • MEIP $6.91
  • WKHS $8.78
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 36.75
  • WKHS 54.62
  • Support Level
  • MEIP $2.76
  • WKHS $0.88
  • Resistance Level
  • MEIP $2.91
  • WKHS $1.42
  • Average True Range (ATR)
  • MEIP 0.11
  • WKHS 0.22
  • MACD
  • MEIP -0.04
  • WKHS -0.00
  • Stochastic Oscillator
  • MEIP 5.13
  • WKHS 30.58

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About WKHS Workhorse Group Inc.

Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.

Share on Social Networks: